<DOC>
	<DOC>NCT00057681</DOC>
	<brief_summary>This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.</brief_summary>
	<brief_title>Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents</brief_title>
	<detailed_description>Patients are randomly assigned to receive lithium (Eskalith), valproate (Depakote), or risperidone (Risperdal) for 8 to 16 weeks. They will have weekly visits to monitor their response to the medication. When the study is complete, care will be transferred to the child's treating psychiatrist.</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>DSMIV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks CGAS less than or equal to 60 Good physical health Schizophrenia or any pervasive developmental disorder Major medical or neurological disease History of addiction to illicit substances or alcohol or drug abuse within the last 4 weeks IQ less than 70 Pregnancy or breastfeeding Unacceptable methods of contraception Inpatient care at baseline</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Mania</keyword>
</DOC>